Full Text View
Tabular View
Study Results
Related Studies
Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
This study has been completed.
Study NCT00082433   Information provided by Bristol-Myers Squibb
First Received: May 7, 2004   Last Updated: July 2, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cancer
Breast Cancer
Additional conditions recognized in this trial
Breast Neoplasms
More general conditions related to this trial
Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases
Interventions listed in this trial
Ixabepilone + Capecitabine
Capecitabine
Additional drug interventions recognized in this trial
Epothilones
Fluorouracil
More general drug interventions related to this trial
Antimetabolites
Antimetabolites, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
Bristol-Myers Squibb


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services